BTIG analyst Kaveri Pohlman maintained a Buy rating on Shattuck Labs (STTK – Research Report) yesterday and set a price target of $12.00. The company’s shares opened today at $6.99.
According to TipRanks, Pohlman is an analyst with an average return of -11.6% and a 32.50% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Genmab, and Ambrx Biopharma.
Currently, the analyst consensus on Shattuck Labs is a Strong Buy with an average price target of $13.20, implying an 88.84% upside from current levels. In a report released on December 18, Citi also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
STTK market cap is currently $336.1M and has a P/E ratio of -3.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Shattuck Labs (STTK) Company Description:
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company’s product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Read More on STTK:
- Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
- Shattuck Labs prices 4.65M shares at $6.45 in registered offering
- Largest borrow rate increases among liquid names
- Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
- Shattuck Labs announces data from Phase 1A/B clinical trial of SL-172154
